ProQR Therapeutics Crecimiento futuro

Future controles de criterios 2/6

ProQR TherapeuticsSe prevé que los beneficios de la empresa disminuyan en 0.3% al año, mientras que sus ingresos anuales crecerán en 22.1% al año. Se espera que el BPA de grow sea de 4.5% al año.

Información clave

-0.3%

Tasa de crecimiento de los beneficios

4.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	21.1%
Tasa de crecimiento de los ingresos	22.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	18 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

Mar 17

ProQR says EU regulator seeks additional trial for lead candidate

Aug 11

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Nov 10

Investment Case On ProQR Therapeutics Gets More Enticing

Oct 01

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Aug 04

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

Jun 20

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

May 13

ProQR Therapeutics offers a de-risked opportunity: Stifel

May 03

If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Mar 08

Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

Feb 01

ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder

Jan 07

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Dec 28

A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

Dec 01

ProQR reports Q3 results

Nov 16

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:PRQR - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	15	-46	-57	-57	3
12/31/2025	24	-31	-19	-35	3
12/31/2024	20	-36	-21	-35	5
12/31/2023	7	-28	28	22	N/A
9/30/2023	5	-37	8	9	N/A
6/30/2023	4	-54	1	1	N/A
3/31/2023	4	-60	-4	-3	N/A
12/31/2022	4	-64	-69	-69	N/A
9/30/2022	4	-69	-48	-47	N/A
6/30/2022	4	-61	-40	-40	N/A
3/31/2022	3	-63	-35	-35	N/A
12/31/2021	2	-61	-26	-26	N/A
9/30/2021	2	-57	-42	-42	N/A
6/30/2021	2	-55	-44	-43	N/A
3/31/2021	1	-43	-45	-44	N/A
12/31/2020	1	-47	-48	-47	N/A
9/30/2020	1	-52	-48	-47	N/A
6/30/2020	1	-51	-47	-46	N/A
3/31/2020	2	-58	-47	-47	N/A
12/31/2019	2	-56	-45	-44	N/A
9/30/2019	3	-51	-41	-41	N/A
6/30/2019	5	-45	-37	-37	N/A
3/31/2019	6	-40	-32	-31	N/A
12/31/2018	6	-37	-29	-28	N/A
9/30/2018	4	-35	-28	-28	N/A
6/30/2018	2	-40	-32	-31	N/A
3/31/2018	1	-44	-36	-36	N/A
12/31/2017	1	-44	-35	-35	N/A
9/30/2017	1	-41	N/A	-34	N/A
6/30/2017	1	-41	N/A	-37	N/A
3/31/2017	1	-39	N/A	-35	N/A
12/31/2016	2	-39	N/A	-34	N/A
9/30/2016	3	-36	N/A	-34	N/A
6/30/2016	3	-33	N/A	-29	N/A
3/31/2016	3	-31	N/A	-27	N/A
12/31/2015	3	-21	N/A	-24	N/A
9/30/2015	3	-17	N/A	-22	N/A
6/30/2015	1	-14	N/A	-20	N/A
3/31/2015	1	-10	N/A	-18	N/A
12/31/2014	0	-12	N/A	-14	N/A
9/30/2014	0	-12	N/A	-10	N/A
6/30/2014	0	-9	N/A	-7	N/A
3/31/2014	0	-5	N/A	-4	N/A
12/31/2013	0	-3	N/A	-2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: PRQR se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: PRQR se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: PRQR se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: PRQRSe prevé que los ingresos de la empresa (17.8% al año) crezcan más deprisa que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: PRQRSe prevé que los ingresos de la empresa (20.4% al año) crezcan más deprisa que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PRQR se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

ProQR Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 64%, EPS downgraded

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 15%

Consensus revenue estimates fall by 16%

Consensus revenue estimates decrease by 25%

Consensus EPS estimates upgraded to €0.24 loss, revenue downgraded

Recent updates

ProQR Therapeutics N.V. Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Consensus revenue estimates increase by 64%, EPS downgraded

Third quarter 2023 earnings released: €0.07 loss per share (vs €0.33 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 11%

Laboratoires Théa S.A.S. acquired Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. (NasdaqCM:PRQR) for approximately €170 million.

New minor risk - Share price stability

Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Consensus revenue estimates increase by 15%

Consensus revenue estimates fall by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Laboratoires Théa S.A.S. agreed to acquire Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. (NasdaqCM:PRQR) for approximately €135 million.

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Consensus revenue estimates decrease by 25%

Consensus EPS estimates upgraded to €0.24 loss, revenue downgraded

Price target decreased by 9.2% to US$3.82

ProQR Therapeutics N.V. Approves the Appointment of Theresa Heggie and Begoña Carreño as Supervisory Board Member

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2023

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

Price target increased to US$3.25

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

ProQR Therapeutics N.V. Appoints Jurriaan Dekkers as Chief Financial Officer

Consensus forecasts updated

ProQR Therapeutics N.V. to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

Consensus revenue estimates increase by 25%

ProQR says EU regulator seeks additional trial for lead candidate

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ProQR Therapeutics N.V. Appoints Rene Beukema as Member of Management Board

ProQR Therapeutics N.V., Annual General Meeting, Jun 30, 2022

Consensus estimates of losses per share improve by 11%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$3.29

Price target decreased to US$3.64

ProQR Therapeutics N.V. Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy

Foundation Fighting Blindness and InformedDNA Partner to Engage and Screen Patients for Proqr's Pivotal Usher Syndrome and Retinitis Pigmentosa Clinical Trials

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$13.50

ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10

ProQR Therapeutics N.V. Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen

ProQR Therapeutics N.V. Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421A for USH2A Mediated Retinitis Pigmentosa

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Investment Case On ProQR Therapeutics Gets More Enticing

Consensus forecasts updated

Phoenicis Therapeutics Inc. acquired Wings Therapeutics, Inc from ProQR Therapeutics N.V. (NasdaqGM:PRQR) and others.

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

Consensus forecasts updated

ProQR Therapeutics offers a de-risked opportunity: Stifel

Price target increased to US$24.17

ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome

If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Revenue and earnings beat expectations

Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

New 90-day high: US$5.27

ProQR Therapeutics N.V. Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10

ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

New 90-day low: US$3.58

A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

Revenue and earnings beat expectations